Sartorius To Acquire Polyplus for $2.6 Bn
Sartorius, a provider of products and services for the life-sciences, including bioprocessing, has agreed to acquire Polyplus, a provider of upstream products and services for advanced biologic and cell- and gene-therapy production, for approximately EUR 2.4 billion ($2.6 billion) from private investors, including Archimed and WP GG Holdings IV, an affiliate of Warburg Pincus.
Polyplus has around 270 employees and develops and produces transfection as well as other DNA/RNA delivery reagents and plasmid DNA and GMP-grade materials. These are key components in the production of viral vectors used in cell and gene therapies and other advanced medicinal therapeutic products. Polyplus is based in Strasbourg, France, and has locations in France, Belgium, the US, and China. The company has been expanding its focus beyond transfection reagents through acquisitions in adjacent technologies, such as plasmid design and protein and plasmid manufacturing as well as broadening its upstream portfolio for gene therapies as well as gene-modified cell therapies.
The proposed transaction is subject to customary conditions, including completion of the information and consultation of work councils and approval by regulatory authorities and is expected to close during the third quarter of 2023.
